JO3246B1 - اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري - Google Patents

اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Info

Publication number
JO3246B1
JO3246B1 JOP/2010/0293A JOP20100293A JO3246B1 JO 3246 B1 JO3246 B1 JO 3246B1 JO P20100293 A JOP20100293 A JO P20100293A JO 3246 B1 JO3246 B1 JO 3246B1
Authority
JO
Jordan
Prior art keywords
protease
human
antibodies
high affinity
activated receptor
Prior art date
Application number
JOP/2010/0293A
Other languages
English (en)
Inventor
J Murphy Andrew
R Salzler Robert
Macdonald Lynn
R Morra Marc
L Lacroix-Fralish Michael
J Papadopoulos Nicholas
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3246B1 publication Critical patent/JO3246B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع بتوفير اجسام مضادة ترتبط بمستقبل منشط 2- للبروتياز ( PAR-2) وطرق لاستخدامه . وطبقاً لنماذج معينة من الاختراع تكون الأجسام المضادة عبارة عن اجسام مضادة بشرية كاملة ترتبط ب PAR-2 البشري. تكون الجسام المضادة للاختراع مفيدة من بين أشياء أخرى، في معالجة الأمراض والاضطرابات المرتبطة بواحد او أكثر من الأنشطة البيولوجية ل PAR-2 ، بما في ذلك معالجة حالات الألم والحالات الالتهابية وحالات المعدة والامعاء.
JOP/2010/0293A 2009-09-09 2010-08-23 اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري JO3246B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US24282109P 2009-09-16 2009-09-16
US31783910P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
JO3246B1 true JO3246B1 (ar) 2018-03-08

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0293A JO3246B1 (ar) 2009-09-09 2010-08-23 اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Country Status (29)

Country Link
US (3) US8101724B2 (ar)
EP (1) EP2475684B1 (ar)
JP (2) JP5832435B2 (ar)
KR (1) KR101766701B1 (ar)
CN (1) CN102574923B (ar)
AR (1) AR078346A1 (ar)
AU (1) AU2010292342C1 (ar)
BR (1) BR112012005338A2 (ar)
CA (1) CA2773541A1 (ar)
CY (1) CY1118714T1 (ar)
DK (1) DK2475684T3 (ar)
ES (1) ES2609780T3 (ar)
HR (1) HRP20170324T1 (ar)
HU (1) HUE031725T2 (ar)
IL (1) IL218501A (ar)
JO (1) JO3246B1 (ar)
LT (1) LT2475684T (ar)
MX (1) MX2012002927A (ar)
MY (1) MY159551A (ar)
NZ (1) NZ599204A (ar)
PL (1) PL2475684T3 (ar)
PT (1) PT2475684T (ar)
SG (1) SG178976A1 (ar)
SI (1) SI2475684T1 (ar)
SM (2) SMT201700102T1 (ar)
TW (1) TWI492757B (ar)
UY (1) UY32883A (ar)
WO (1) WO2011031695A1 (ar)
ZA (1) ZA201201730B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP3434691A1 (en) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
KR20160060120A (ko) 2013-09-25 2016-05-27 버텍스 파마슈티칼스 인코포레이티드 Ｐａｒ-2 신호전달 경로의 억제제로서 유용한 이미다조피리다진
US10519222B2 (en) * 2014-02-28 2019-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
AU2017356860A1 (en) 2016-11-08 2019-05-16 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
PH12021551676A1 (en) * 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
AU2020281380B2 (en) * 2019-05-30 2024-04-11 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
JP7263538B2 (ja) * 2019-11-01 2023-04-24 株式会社 資生堂 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤
CN113248611A (zh) * 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
WO2021202770A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Human anti-cd33 antibodies and uses thereof
PE20231187A1 (es) 2020-08-18 2023-08-15 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos
JP2024535740A (ja) * 2021-09-02 2024-10-02 メモリアル スローン ケタリング キャンサー センター Ｃｄ３３を標的とする抗原認識受容体及びその使用
WO2023034564A2 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-cd33 antibodies and uses thereof
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763575A (en) * 1993-07-26 1998-06-09 Cor Therapeutics, Inc. Agonist and antagonist peptides of the C140 receptor
ES2301183T3 (es) * 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) * 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
CN102458156A (zh) 2009-06-18 2012-05-16 株式会社爱茉莉太平洋 含有栗子皮提取物的健康食品或药学组合物
WO2010147441A2 (ko) 2009-06-18 2010-12-23 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 화장료 조성물
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
EP2475684B1 (en) 2016-11-30
JP5832435B2 (ja) 2015-12-16
HK1166509A1 (en) 2012-11-02
AU2010292342A1 (en) 2012-05-03
SMT201700102B (it) 2017-03-08
ES2609780T3 (es) 2017-04-24
US20140179903A1 (en) 2014-06-26
JP2015227381A (ja) 2015-12-17
JP6055055B2 (ja) 2016-12-27
BR112012005338A2 (pt) 2016-11-22
US20110059095A1 (en) 2011-03-10
PL2475684T3 (pl) 2017-04-28
IL218501A (en) 2017-03-30
US20120093824A1 (en) 2012-04-19
US9028819B2 (en) 2015-05-12
MX2012002927A (es) 2012-08-03
HUE031725T2 (en) 2017-08-28
CY1118714T1 (el) 2017-07-12
US8425907B2 (en) 2013-04-23
US8101724B2 (en) 2012-01-24
CN102574923B (zh) 2016-12-07
EP2475684A1 (en) 2012-07-18
ZA201201730B (en) 2012-11-28
CN102574923A (zh) 2012-07-11
SG178976A1 (en) 2012-04-27
HRP20170324T1 (hr) 2017-04-21
CA2773541A1 (en) 2011-03-17
WO2011031695A1 (en) 2011-03-17
TW201121565A (en) 2011-07-01
LT2475684T (lt) 2017-01-25
AR078346A1 (es) 2011-11-02
DK2475684T3 (en) 2017-03-06
PT2475684T (pt) 2017-02-10
IL218501A0 (en) 2012-07-31
NZ599204A (en) 2014-05-30
KR101766701B1 (ko) 2017-08-09
TWI492757B (zh) 2015-07-21
SI2475684T1 (sl) 2017-03-31
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
AU2010292342B2 (en) 2015-04-30
AU2010292342C1 (en) 2015-08-27
JP2013504577A (ja) 2013-02-07
KR20120059611A (ko) 2012-06-08
UY32883A (es) 2011-03-31

Similar Documents

Publication Publication Date Title
JO3246B1 (ar) اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
EA201370081A1 (ru) Антитела к cd48 и их применение
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EP2575856A4 (en) INNOVATIVE DETECTION OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201300239A1 (ru) Антитела к fap и способы их применения
UY32603A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EA201290590A1 (ru) Модифицированные туберкулезные антигены
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EP2563912A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
CY1112912T1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
EP2582660A4 (en) NEW CATHEPSIN S PROTEASE INHIBITORS FOR THE TREATMENT OF e.g. AUTOIMMUNE DISEASES, ALLERGIES AND CHRONIC PAIN STATES
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana